Ladenburg Downgrades Micromet (MITI) to Neutral
More News related to MITI
- Micromet (MITI) Enters Agreement with Lonza AG to Develop Blinatumomab
- Micromet Enters Into Agreement With Lonza for the Manufacture of Blinatumomab
- Micromet to Present at The Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
- Micromet, Inc. Replay of Third Quarter 2009 Financial Results Conference Call Now Available
- Micromet, Inc. Reports Third Quarter 2009 Financial Results
Ladenburg Thalmann downgrades Micromet (Nasdaq: MITI) from Buy to Neutral while maintaining its $7 price target. The firm cited valuation.
The downgrade follows news this morning that Micromet has reported interim data from a Phase 1 study of BiTE Antibody MT110.
The stock has tumbled more than 8% on the news.
Click here to see all the analyst upgrades/downgrades on shares of Micromet.
Micromet, Inc., a biopharmaceutical company, engages in the development and sale of antibodies for the treatment of cancer, inflammation, and autoimmune diseases.
Related Categories
DowngradesStocks Mentioned
-0.22Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
